A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Launched by IPSEN · Apr 29, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating how effective and safe a combination treatment of cabozantinib and nivolumab is for adults with advanced renal cell carcinoma (aRCC) that has a clear cell component. This means that the study is looking at how well these two medications work together when given as the first treatment option for this specific type of kidney cancer. It's important to note that the decision to use this combination treatment will be made by the doctor before the patient joins the study.

To be eligible for this trial, participants need to be adults who have been diagnosed with aRCC that has a clear cell component and have not received any prior systemic treatments for it. They also should not have any allergies to the medications being studied. If someone qualifies and decides to participate, they will receive the combination treatment as part of their care, and researchers will collect data on how well the treatment works and any side effects experienced. The trial is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants with diagnosis of aRCC with clear-cell component
• • Participants with no prior systemic treatment for aRCC with clear-cell component;
• • Physician-initiated decision to treat with cabozantinib and nivolumab in combination (prior to study enrolment), according to Cabometyx® and Opdivo® approved local labels;
• Exclusion Criteria:
• • Current participation in an investigational program with any intervention which could possibly interfere the treatment and impact this study;
• • History of allergy or hypersensitivity to Cabometyx® or Opdivo® components.